Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. Post author:Sam Post published:December 18, 2017 Post category:BioPharma The FDA broke new ground today with a first-of-its-kind therapy for eye disease. Source: BioSpace You Might Also Like Insulet, Mayo Clinic Jump in On $35 Million Series C Funding Round June 27, 2017 Ignyta Announces Proposed Public Offering Of Common Stock May 2, 2017 Auris Med Announces Receipt Of Nasdaq Notice August 24, 2017
